Suppr超能文献

大鼠肝微粒体对格列齐特的羟基化作用。

Gliclazide hydroxylation by rat liver microsomes.

作者信息

Rieutord A, Stupans I, Shenfield G M, Gross A S

机构信息

Department of Clinical Pharmacology, Royal North Shore Hospital, St Leonards, NSW, Australia.

出版信息

Xenobiotica. 1995 Dec;25(12):1345-54. doi: 10.3109/00498259509061922.

Abstract
  1. The metabolism of gliclazide to hydroxygliclazide has been investigated in Sprague-Dawley rat liver microsomes. 2. The kinetics of hydroxygliclazide formation are consistent with Michaelis-Menten kinetics (mean (+/- SD, n = 3) apparent K(m) and Vmax = 256 +/- 27 microM and 1.85 +/- 0.10 nmol/ min/mg respectively). 3. Tolbutamide competitively inhibited hydroxygliclazide formation (Ki = 840 microM) and gliclazide competitively inhibited hydroxytolbutamide formation (Ki = 240 microM) with Ki similar to K(m). Therefore gliclazide and tolbutamide may be metabolized by the same enzyme in the rat. In nine livers the formation of hydroxygliclazide correlated with the formation of hydroxytolbutamide (rs = 0.82, p < 0.01). 4. Diclofenac (Ki = 64 microM), phenytoin (Ki = 38 microM), mephenytoin (Ki = 66 microM), glibenclamide (Ki = 14 microM) and glipizide (Ki = 189 microM) were fully competitive inhibitors of gliclazide hydroxylation. The rank order of Ki constants differed for gliclazide and tolbutamide suggesting that gliclazide and tolbutamide hydroxylases are not identical enzymes. 5. Quinine (Ki = 0.3 microM) and quinidine (Ki = 4.3 microM) were partially competitive inhibitors of hydroxygliclazide formation. Hydroxylation of gliclazide was related to the activity of CYP2D1 as assessed by dextrorphan production from dextromethorphan (rs = 0.83, p = 0.01). 6. In the rat gliclazide is metabolized to hydroxygliclazide by at least two cytochrome P450 isoforms, including tolbutamide hydroxylase and 2D1, which have similar affinities for gliclazide.
摘要
  1. 已在斯普拉格-道利大鼠肝微粒体中研究了格列齐特代谢为羟基格列齐特的过程。2. 羟基格列齐特形成的动力学符合米氏动力学(平均值(±标准差,n = 3)表观K(m)和Vmax分别为256±27微摩尔和1.85±0.10纳摩尔/分钟/毫克)。3. 甲苯磺丁脲竞争性抑制羟基格列齐特的形成(Ki = 840微摩尔),格列齐特竞争性抑制羟基甲苯磺丁脲的形成(Ki = 240微摩尔),Ki与K(m)相似。因此,格列齐特和甲苯磺丁脲可能在大鼠体内由同一种酶代谢。在九个肝脏中,羟基格列齐特的形成与羟基甲苯磺丁脲的形成相关(rs = 0.82,p < 0.01)。4. 双氯芬酸(Ki = 64微摩尔)、苯妥英(Ki = 38微摩尔)、美芬妥英(Ki = 66微摩尔)、格列本脲(Ki = 14微摩尔)和格列吡嗪(Ki = 189微摩尔)是格列齐特羟基化的完全竞争性抑制剂。格列齐特和甲苯磺丁脲的Ki常数排序不同,表明格列齐特羟化酶和甲苯磺丁脲羟化酶不是同一种酶。5. 奎宁(Ki = 0.3微摩尔)和奎尼丁(Ki = 4.3微摩尔)是羟基格列齐特形成的部分竞争性抑制剂。格列齐特的羟基化与通过右美沙芬产生右啡烷评估的CYP2D1活性相关(rs = 0.83,p = 0.01)。6. 在大鼠体内,格列齐特至少通过两种细胞色素P450同工型代谢为羟基格列齐特,包括甲苯磺丁脲羟化酶和2D1,它们对格列齐特具有相似的亲和力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验